A phase II study of obatoclax mesylate (GX15-070MS) in patients with previously-untreated myelodysplastic syndromes (MDS) with anemia and/or thrombocytopenia.

Trial Profile

A phase II study of obatoclax mesylate (GX15-070MS) in patients with previously-untreated myelodysplastic syndromes (MDS) with anemia and/or thrombocytopenia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Obatoclax (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2012 Company (Teva Pharmaceutical Industries) added as reported by ClinicalTrials.gov.
    • 14 Sep 2010 Additional lead trial investigator (Mark Berger) identified as reported by ClinicalTrials.gov.
    • 14 Sep 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top